Eli Lilly & Co. (NYSE: LLY) shares hiked 5% to $86.37. The company won a patent case in the U.K. that bans competitors from making a generic form of its Alimta cancer drug, The Wall Street Journal reported. The stock was also upgraded to buy from neutral at Bank of America Merrill Lynch, according to 24/7 WallSt.com. Share volume was 1.1 million, compared to an all-day average of 1.3 million
